Type 2 diabetes (T2D) has reached pandemic proportions worldwide. Almost half of T2D patients suffer from polyneuropathy that can present as paresthesia, hyperalgesia, allodynia, or hypoesthesia. Therapeutic treatment options are largely incomplete, suggesting new avenues of research are needed. Herein, we introduce the African Nile Grass rat (NGR), which develops T2D solely by diet manipulation, as a novel T2D polyneuropathy model. The purpose of this study was to first characterize T2D-induced polyneuropathy in the NGRs before highlighting their strength as a potential prediabetic model of T2D. NGRs with long-term T2D exhibit hallmark features of polyneuropathy such as decreased motor nerve conduction velocity, intraepidermal denervation, and hyposensitivity to noxious mechanical and thermal stimulation. At the dorsal root ganglia, T2D neurons have altered sodium channel expression, specifically increased Nav1.7 and Nav1.9, and their surrounding satellite glial cells express glial fibrillary acidic protein. Now that these T2D NGRs have been characterized and shown to have a similar presentation to human and other animal models of T2D, the strength of this diet-induced model can be exploited. The prediabetic changes can be observed over their long progression to develop T2D which may allow for a therapeutic window to prevent T2D before permanent damage occurs.
INTRODUCTION
Type 2 diabetes mellitus (T2D) accounts for over 90% of all diagnosed cases of diabetes and its prevalence has almost quadrupled since 1980 (1) . T2D exceeds 400 million adult patients worldwide and almost half of these patients will develop polyneuropathy due to nerve damage from chronic hyperglycemia (2, 3) . T2D-induced polyneuropathy often affects the distal hands and feet in a symmetrical fashion and it can present as paresthesia, hyperalgesia, allodynia, spontaneous pain, or hypoesthesia (numbness). Painful polyneuropathy occurs in 10%-30% of T2D patients (4) (5) (6) , whereas up to 50% of patients have hypoesthesia (7) . Hypoesthesia may allow tissue damage to go unnoticed, increasing the risk of infection that may necessitate amputation. Pharmacological treatment of diabetic polyneuropathy is inadequate, in part attributable to our limited understanding of the pathophysiology of the disease.
A recent diabetic polyneuropathy task force established by NEURODIAB reported a need for new T2D animal models that mimic all aspects of the human condition including hyperglycemia, dyslipidemia, hypertension and microangiopathy (8) . To mirror patients, new models will ideally have extended prediabetes to allow for the study of the early pathogenesis of T2D polyneuropathy. This will allow for testing within key therapeutic windows aimed at halting early progression. In this study, we investigated polyneuropathy in a diet-induced T2D animal model, the African Nile Grass rat (NGR) that develops T2D without pharmacological agents or experimental manipulations (9) . The majority of NGRs fed with a high calorie, low fiber diet (common laboratory rat chow) develops T2D whereas these rats fed on a high-fiber, low-fat diet, similar to their native diet of grass and seeds, remain healthy (10) . An interesting feature of this model is that the intensity of hyperglycemia is lower but prolonged, in contrast to many models that exclusively study rodents with fasting blood glucose (FBG) levels of !16.0 mmol/L (11, 12) . The development of T2D in these animals compliments the NEURODIAB requirements for a new diabetic model; their etiopathogenesis parallels that of humans, first presenting with hyperinsulinemia (2 months) followed by hyperglycemia (6-12 months) , and progressing to pancreatic b-cell dysfunction, dyslipidemia, weight gain, microvascular pathology, hypertension and ketonuria (>12 months) (8, 9, 13) .
Polyneuropathy in this unique model had not previously been addressed. We hypothesized that unlike those fed with a high-fiber, low-fat diet, NGRs fed with the chow diet will develop T2D-induced polyneuropathy. This study revealed that, similar to T2D polyneuropathy in patients, T2D NGRs demonstrated hyperglycemia, mechanical and thermal behavioral hyposensitivity, epidermal denervation, and distal slowing of motor nerve conduction velocity (NCV) (14, 15) . We confirmed changes in voltage gated sodium channel (Nav) expression and activation of satellite glial cells at the dorsal root ganglia (9, (16) (17) (18) (19) . Collectively, our findings characterize a unique model of T2D polyneuropathy.
The establishment of the NGR as a diet-induced model of T2D polyneuropathy will provide a basis for future studies into the etiopathogenesis of polyneuropathy at the prediabetic and acute diabetic stages. As there are no pharmacological or genetic manipulations to induce T2D, NGRs have a long progression of prediabetes that may allow for the opportunity to test therapies at early time-points when successful intervention is most likely.
MATERIALS AND METHODS

Animals
Thirty-six male NGRs (12 control, 24 T2D) were used in this study. All animals were housed and maintained as described (9) . Control NGRs were fed with high-fiber, low-fat ("Mazuri chinchilla" diet; 5M01, Purina Mills, St Louis, MO) and prospective T2D NGRs with standard laboratory rat chow diet (Prolab RMH 2000, LabDiet, Nutrition International, Richmond, IN). The animals were euthanized by Euthanyl injection (480 mg/kg) (9) . All protocols were approved by University of Alberta Animal Ethics Committee and all experiments were carried out in accordance with Canadian Council on Animal Care guidelines (20) . In all experiments, researchers were blinded to the identity of the animal.
Fasting Blood Glucose
NGRs were deprived of food 16 hours prior to measuring FBG. Glucose was measured from tail blood samples as described and animals with FBG >5.6 mmol/L were considered hyperglycemic (9) . Animals were considered to have comorbidities if their average plasma insulin level was below 2 ng/mL and body weight was less than 120 g (9) .
Nerve Conduction Studies
The NGRs were anaesthetized with oral isoflurane (5%) and sciatic motor NCV studies were performed by electrical stimulation (DS5 stimulator, Digitimer, Ltd., Hertfordshire, UK) at the sciatic notch or popliteal fossa. The tibial nerve was stimulated at 1.0 Hz and the stimulation intensity was increased until a compound muscle action potential (CMAP) was evoked. The CMAP was recorded using subdermal needle electrodes at the foot interossei muscles as described (21) . The distance from the stimulation points to the site of recording at the foot muscles was measured to determine the tibial NCV.
Von-Frey Test
The animals were habituated on a mesh platform chamber and their foot withdrawal response to incremental force applied by calibrated Von-Frey filaments (0.04-6 g) was recorded. Tests were repeated 5 times per filament on both left and right paws and the threshold was recorded if a positive response (paw withdrawal, flinching or licking) was observed in at least 3 of the 5 tests (22) . The average thresholds from both paws were recorded per animal.
Hargreaves Test
The animals were habituated for 1 hour in the Hargreaves chamber prior to plantar footpad laser stimulation (52 C) and the paw withdrawal latency (seconds, s) was measured automatically. The test was repeated 3 times on both the left and right paws and the average withdrawal latency was calculated.
Immunohistochemistry
Footpad skin was harvested using a 3-mm punch biopsy, fixed in 2% PLP (paraformaldehyde, lysine, periodate) fixative overnight at 4 C and cryoprotected in 20% glycerol/0.1 M Sorenson's phosphate buffer (11, 21) . The tissue was cut into 20 mm sagittal sections and dried onto Superfrost Plus microscope slides (Thermo Fisher Scientific, Waltham, MA). Tissues were processed for antigen retrieval in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) for 20 minutes at 85 C. The slides washed in PBS and permeabilized in 1% Triton-X for 10 minutes. The tissues were blocked for 1 hour at RT in 10% normal goat serum, 1% BSA, 0.3% Triton-X, and 0.05% Tween 20 in PBS and incubated overnight at 4 C in primary rabbit polyclonal antibody, PGP9.5, solution (1:200, EnCor Biotechnology, Gainesville, FL). After rinsing in PBS, the tissues were incubated for 2 hours with Cy3 anti-rabbit IgG (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA), washed, and mounted with polyaquamount (Polysciences, Inc., Warrington, PA). Images were captured with a Zeiss Observer Z1 inverted fluorescent microscope at 40Â magnification. Intraepidermal nerve fibers (IENFs) labeled with PGP9.5 were counted in 4-6 adjacent fields of at least 3 sections per animal for a total of 12-18 fields per NGR using ImageJ (16, 23) and IENFs density (number of PGP9.5 axons/mm) was calculated.
Lumbar L4 and L5 DRGs were isolated and fixed in 4% paraformaldehyde overnight at 4 C and cryoprotected in 30% sucrose (20) . Tissue sections (12 mm) were processed for antigen retrieval, washed and permeabilized as above. The slides were incubated for 1 hour in blocking solution containing 10% normal goat serum and 3% BSA and incubated overnight in the following primary antibodies: Mouse anti-peripherin (1:500, Sigma Aldrich, St. Louis, MO), rabbit anti-neurofilament 200 (NF200) (1:500, Sigma Aldrich), rabbit anti-calcitonin gene-related peptide (CGRP) (1:500, Sigma Aldrich), rabbit anti-glial fibrillary acidic protein (GFAP) (1:500, Dako, Mississauga, Canada), rabbit anti-Nav1.7, rabbit anti-Nav1.9 and rabbit anti-Nav1.8 (1:500, Alomone Labs, Jerusalem, Is-rael). The sections were washed in PBS and incubated with Cy3 anti-rabbit IgG or AlexaFluor 488 secondary antibodies (1:500). Nuclei were labeled with NucBlue Live Cell Stain (Life Technologies, Grand Island, NY). The DRG sections were imaged at 20Â magnification. Using the freehand selection tool (ImageJ software), each DRG neuron (DRGN) soma with a visible nucleus was circled and the fluorescence intensity (average grey intensity/mm 2 ) was represented as arbitrary units (au) (24, 25) . Using ImageJ software, an intensity threshold was set (25) and all DRGN with staining intensity above this threshold was considered positively labeled. These data were represented by scatterplots prepared using Graphpad Prism software (1 scatterplot per DRG section). The average of at least 3 DRG sections from 2 separate slides was measured for each animal.
qRT-PCR
Isolated DRGs were processed for quantitative real-time PCR (qRT-PCR) as described (26) . Total RNA (200 ng) was converted to cDNA using Superscript III Reverse Transcriptase (Invitrogen, Carlsbad, CA) and oligo (dT) [12] [13] [14] [15] [16] [17] [18] primers (Invitrogen). Resulting cDNA was transcribed in a FAST Sybr Green (Applied Biosystems, Foster City, CA) qRT-PCR reaction using StepOne Plus System (Life Technologies, Carlsbad, CA). The following primers were used to for qRT-PCR reaction: Nav1.7, Nav1.9 and Nav1.8 (Qiagen, Hilden, Germany); LCGRP (peptide): Fw-CCAGATAAGCCAGAACCATGC, Rev-CCCTTCTCCCTATGACAGGAAA; ACGRP (receptor): Fw-AGCTAAGATGAGC GCAA GT, Rev-CCCTTC TCCCTATGACAGGAAA; HPRT: Fw-AGCCTAAGATGA GCGCAAGT, Rev-TTACTAGGCAGATGGCCACA. Data were analyzed on a base-2 logarithmic scale.
Statistical Analysis
All results were presented as standard error of mean (SEM). Statistical significance was performed between control and T2D groups using unpaired Student's t-test, with significance of at least p < 0.05.
RESULTS
T2D NGRs Develop Diabetic Polyneuropathy
Of the 24 male chow-fed NGRs used in this study, 79.1% were hyperglycemic as their FBG levels exceeded 5.6 mmol/L (9). The remaining 21.9% were not hyperglycemic at the time of euthanization, however, their T2D was verified based on comorbidities (9) (Tables 1, 2). None of the control NGRs (n ¼ 12) displayed hyperglycemia.
Our first aim was to demonstrate that NGRs exhibit the hallmark features of T2D-induced polyneuropathy, including IENF denervation, decreased motor NCV and altered pain response to noxious mechanical and thermal stimuli. Footpad skin biopsies obtained from T2D and control NGRs were processed for immunocytochemistry against the small nerve fiber protein gene product 9.5 (PGP9.5) to count IENFs (Ad and C fibers). There was a marked epidermal denervation in the footpads of T2D NGRs (16.6 6 1.9 nerve terminals/mm, n ¼ 9) compared with control (25.8 6 1.5 nerve terminals/mm, n ¼ 5,
Response to mechanical stimuli was tested with calibrated Von-Frey filaments (0.4-6.0 g). T2D NGRs required greater mechanical force (2.1 6 0.6 g, n ¼ 10) to elicit paw-withdrawal compared with control animals (0.7 6 0.1 g, n ¼ 7, p < 0.05; Fig. 1D ). An upper limit of 6 g of force was determined as this filament physically lifted the paw off the mesh without evoking a withdrawal response. T2D NGRs also displayed thermal hyposensitivity as it took them longer (16.0 6 1.1 s, n ¼ 10) to remove their paws from 52 C noxious heat compared with controls (11.5 6 1.1 s, n ¼ 7, p < 0.05; Fig. 1E ). Sciatic motor NCV slowed from 68.0 6 0.8 m/s (n ¼ 5) in control NGRs to 26.9 6 2.3 m/s (n ¼ 7, p < 0.001) in T2D NGRs (Fig. 1F, G) . Collectively, our data indicate that T2D NGRs display common features of polyneuropathy including skin denervation, decreased motor NCV and hyposensitivity to noxious mechanical and thermal stimulation.
T2D Activates Satellite Glial Cells at the DRG
Large and small diameter DRGNs were coimmunolabeled with classic markers to ensure T2D did not affect the overall gross distribution DRGN subpopulations. Large diameter mechanosensory and proprioceptive DRGNs were labeled with NF200, whereas small diameter DRGNs, comprised primarily of nociceptive neurons, were labeled with peripherin ( Fig. 2A-F) . Representative scatterplots of immunolabeled DRG tissue sections illustrates both DRG cell body diameter and fluorescent labeling intensity of NF200 (Fig. 2G , H) and peripherin (Fig. 2I, J) . Semiquantitative analysis determined that there was no change in the NF200 labeling intensity of the T2D DRGNs (48.8 6 1.1 au, n ¼ 3, 10 DRG) compared with the controls (51.0 6 1.7 au, n ¼ 3, 11 DRG, p ¼ 0.30; Fig. 2K ). Similarly, there was no difference in the percentage of large diameter DRGNs expressing NF200 when comparing T2D NGRs (38.7% 6 4.6%, n ¼ 3, 10 DRG) to controls (52.4% 6 5.2%, n ¼ 3, 11 DRG, p ¼ 0.06; Fig. 2L ). There were no changes in the peripherin labeling intensity of T2D DRGNs (31.6 6 2.5 au, n ¼ 3, 10 DRG) compared with the controls (28.0 6 2.2 au, n ¼ 3, 9 DRG, p ¼ 0.29; Fig. 2M ). Similarly, there was no difference in the percentage of small diameter DRGNs expressing peripherin in T2D NGRs (68.6% 6 8.4%, n ¼ 3, 10 DRG) and control (55.9% 6 6.2%, n ¼ 3, 9 DRG, p ¼ 0.25; Fig. 2N ).
We went on to determine if there were differences in peptidergic and nonpeptidergic populations of DRGNs from NGR with or without T2D. Peptidergic DRGNs, which express calcitonin gene related peptide (CGRP), modulate sharp pain perception and have a pronociceptive role in peripheral nerve injury-induced neuropathic pain (31) . T2D and control DRG were immunolabeled against CGRP (Fig. 3A, B) and representative scatterplots of these sections depicted the neuronal soma diameter and CGRP labeling intensity (Fig. 3C,  D) . Semiquantification of CGRP immunohistochemistry did not reveal significant changes in protein labeling intensity between control (58.4 6 1.9 au, n ¼ 4, 11 DRG) or T2D DRGNs (60.6 6 4.5 au, n ¼ 3, 15 DRG, p ¼ 0.69; Fig. 3E ). Similarly, there was no change in the percentage of CGRPpositive small diameter T2D DRGNs (47.1% 6 7.2%, n ¼ 3, 15 DRG) compared with control (44.8% 6 5.8%, n ¼ 4, 11 DRG; p ¼ 0.81; Fig. 3F ). We did not observe a change in the percentage of IB4-positive (nonpeptidergic) small diameter T2D DRGNs (40.7% 6 7.1%, n ¼ 3, 9 DRG) compared with control DRGNs (42.1% 6 5.2%, n¼ 3, 9 DRG; p ¼ 0.88; Fig. 3G-I) .
GFAP, a marker of satellite glial cell activation, is elevated in multiple types of T2D polyneuropathy (19, 32, 33) . T2D NGRs had 36.5% 6 2. 
T2D Alters Voltage Gated Sodium Channel Expression
Voltage gated sodium channels (Navs) of diverse variants contribute to action potential generation and propagation in neurons. Navs 1.7-1.9 are predominantly expressed in DRGNs and have altered levels in different pathological conditions such as peripheral nerve injury and diabetes (17, (34) (35) (36) (37) . Nav1.7-labeled T2D and control DRGNs were colabeled with NF200 to visualize the large (NF200-expressing) and small (NF200-negative) DRGNs (Fig. 4A-F) . DRG cell body size and Nav1.7 labeling intensity were illustrated by representative scatterplots of T2D and control DRGs. These studies confirmed an increase in Nav1.7 labeling intensity in both the small and large diameter T2D DRGNs (72.0 6 4.1 au; 72.1 6 4.0 au, n ¼ 6, 21 DRGs, respectively) compared with control (49.9 6 1.5 au; 52.0 6 2.1 au, n ¼ 4, 17 DRGs, respectively, p < 0.001; Fig. 4I, J) . Further, there was an increase in the percentage of both small and large diameter T2D DRGNs expressing Nav1.7 (95.0% 6 2.0%; 90.1% 6 2.3%, n ¼ 4, 20 DRGs) compared with small and large diameter controls (78.4% 6 4.8%; 74.0% 6 5.4%, n ¼ 4, 16 DRGs, p < 0.01; Fig. 4K, L) . Quantitative RT-PCRs confirmed there was a significant increase in Nav1.7 mRNA expression in T2D NGRs (2.114 6 0.27 M (log2) , n ¼ 4) compared with control (0.0001 6 0.27 M (log2) , n ¼ 3; p < 0.01; Fig. 4M ).
We demonstrated a significant increase in Nav1.9 labeling intensity of the small diameter T2D DRGNs (56.6 6 3.2 au, n ¼ 4, 12 DRGs) compared with control (47.4 6 1.1 au, n ¼ 3, 13 DRGs, p < 0.05; Fig. 5A-I) ; however, there was no change in the percentage of small diameter T2D DRGNs expressing Nav1.9 (88.0% 6 4.5%, n ¼ 4, 12 DRGs) compared with control (85.2% 6 3.5%, n ¼ 3, 13 DRGs, p ¼ 0.63; Fig. 5K ). Further, there was no change in labeling intensity of Nav1.9 protein in the T2D large diameter neurons (54.9 6 2.9 au, n ¼ 4, 12 DRGs) compared with control (50.0 6 1.2 au, n ¼ 3, 13 DRGs, p ¼ 0.23; Fig. 5J ), or the percentage of large diameter T2D neurons expressing Nav1.9 (85.8% 6 6.5%, n ¼ 4, 12 DRGs) compared with control (86.5% 6 5.7%, n ¼ 3, 13 DRGs, p ¼ 0.93; Fig. 5L ). Quantitative RT-PCRs identified a significant increase in Nav1.9 mRNA expression in T2D NGRs (1.312 6 0.18 M (log2) , n ¼ 5) compared with control (0.0004 6 0.16 M (log2) , n¼ 3; p < 0.01; Fig. 5M ).
There was no change in Nav1.8 labeling intensity in either small or large T2D DRGNs (53.3 6 1.9 au; 60.3 6 2.5 au, respectively, n ¼ 6, 18 DRGs) compared with their respective controls (small, 54.4 6 2.1 au, p ¼ 0.69; large, 60.5 6 2.8 au, p ¼ 0.96; n ¼ 4, 14 DRGs; Fig. 6A-J) . Similarly, there was no change in percentage of small or large diameter T2D DRGNs expressing Nav1.8 (small, 70.2% 6 6.0%; large, 76.5% 6 5.1%, n ¼ 5, 17 DRGs) compared with control (small, 77.2% 6 6.2%, p ¼ 0.43; large, 84.9% 6 2.6%, p ¼ 0.19; n ¼ 4, 13 DRGs; Fig. 6K, L) . Quantitative RT-PCR confirmed there was no change in Nav1.8 mRNA expression in T2D DRGs (À1.773 6 0.15 au, n ¼ 5) compared with control (À0.020 6 0.75 au, n ¼ 3, p ¼ 0.14; Fig. 6M ). Collectively, our results confirm elevated Nav1.7 and Nav1.9, but not Nav1.8, channel expression in T2D DRGNs.
DISCUSSION
We demonstrated NGRs with long-term T2D exhibit hallmark features of polyneuropathy such as IENF denervation with concomitant hyposensitivity to both touch and temperature ( Fig. 1) (7, 38, 39 ). This distinct dieback of T2D distal sensory fibers is without obvious neuronal death at the DRG (Figs. 1A, C, 2) , which may suggest that epidermal reinnervation is possible. Further, distal slowing of motor NCV in T2D NGRs (Fig. 1F, G) correlates with clinical presentation of T2D polyneuropathy (40, 41) . Although the etiopathology is unknown, motor NCV slowing is a strong indicator of clinical neuropathy (8, 40) . Notably, T2D-induced NCV slowing is often accompanied by demyelination and altered ion channel expression (such as Navs) (40) .
As activation of Navs occur immediately after neuronal depolarization to contribute to the initiation of action potentials, alteration of Nav channel functioning can play important roles in various physiological disorders. Gain-of-function mutation of these Nav channels (including Nav1.7, Nav1.8, and Nav1.9) has enhanced spontaneous firing and hyperexcitability in DRGNs, thus contributing to pain (37, 42) . Nav1.7 and Nav1.9 are considered "threshold channels" as these channels can amplify subthreshold depolarizing stimuli to rapidly generate high-frequency action potentials (35, 43) . Alternatively, Nav1.8 channel activity generates inward transmembrane current of an action potential rising phase. Nav1.7 channel activation alters the DRGN membrane potential towards the excitation threshold of Nav1.8 channel, thus allowing Nav1.8 channel-induced repetitive firing of DRGNs and resulting in hyperexcitability and hyperalgesia (44) . In diabetic polyneuropathy, it has been reported that expression of Nav1.7 and Nav1.9 is upregulated in both large and small DRGNs resulting in nociceptor hyperexcitability and hyperalgesia (45) (46) (47) (48) .
Inhibition or loss-of-function mutation of these Nav channel alleviates pain and hyperalgesia (48) . Decreased Nav1.8 mRNA expression and increased inward current has been reported in some models of diabetic neuropathy (47, 49) ; however, these findings are variable among other neuropathies (17, 34, 50) . Our results are compatible with previous findings of upregulation of Nav1.7 and Nav1.9 protein and mRNA in T2D NGR DRGNs (Figs. 4 and 5) . Interestingly, we did not see any change in the expression of Nav1.8 channel which has shown to be altered in T2D animal models (Fig. 6 ). However, future electrophysiological studies such as whole cell patch clamp studies or threshold tracking techniques can determine if Nav1.8 channel functional properties are altered in T2D sensory neuropathy. Membrane potential recordings of cultured DRGNs may confirm our findings on altered Nav1.7 and Nav1.9 channel expression in these T2D neurons (17) . These channels may be potential focal points for future clinical targets to treat diabetic neuropathy.
Although we did not observe gross changes in the neuronal subpopulations through immunohistochemical labeling against NF200, peripherin, CGRP, or IB4, these studies do not provide evidence of how these different neuronal populations are functioning. Future electrophysiological studies of individual neurons will determine if they have altered calcium homeostasis and mitochondrial dysfunction, as has been observed previously in other T2D models (51, 52) .
The role of inflammation and satellite glial cells in T2D needs to be explored further. Similar to previous findings that satellite glial cells from streptozotocin-induced diabetes (19, 32) , and other models of peripheral neuropathies (trauma, HIV, or chemotherapy), we also show the T2D NGR satellite glial cells have increased GFAP expression indicating injury and cellular stress (Fig. 3K ).
NGRs as a Unique Preclinical Model to Treat T2D Polyneuropathy
We have demonstrated that T2D NGRs fulfill the necessary requirements put forth by NEURODIAB; their etiopathogenesis parallels that of humans, first presenting with hyperinsulinemia followed by hyperglycemia, and progressing to pancreatic b-cell dysfunction, dyslipidemia, weight gain, microvascular pathology, hypertension and ketonuria (8, 9, 13) . Importantly, however, the purpose of characterizing T2D NGRs as new model for polyneuropathy was not merely to add a new model to the list. Their uniqueness is that NGR T2D progresses "naturally" (i.e. without genetic or pharmacological intervention) (9) . Future investigation into the etiopathology of T2D at various prediabetic stages will establish a timeline at which permanent damage occurs. Their protracted prediabetes can be exploited for early intervention treatment strategies which may establish the NGR as a novel, highly clinically relevant animal model to test new therapies to prevent development of polyneuropathy.
